Luna Diabetes

Executive Summary

Luna Diabetes is a digital health company developing a novel automated insulin delivery system tailored for the large population of people with diabetes who use multiple daily injections (MDI) rather than insulin pumps. Its flagship product, Luna, is a smart, wearable device designed for overnight use that delivers micro-boluses of insulin to improve nighttime glucose control, allowing users to remain untethered during the day. By focusing on the MDI user base—which represents the majority of insulin-dependent diabetics—Luna addresses a significant unmet need for automation without requiring a full switch to pump therapy. The device integrates with existing insulin pens and continuous glucose monitors (CGMs) to provide closed-loop control overnight, potentially reducing hypoglycemia and improving glycemic outcomes. The market opportunity is substantial: over 8 million people in the U.S. use insulin, with a large fraction on MDI. Luna's differentiated approach could capture a meaningful share if clinical evidence demonstrates efficacy and safety. Key success factors include FDA clearance, positive clinical trial results, and partnerships with insulin pen and CGM manufacturers. The company's early-stage nature means near-term catalysts focus on regulatory milestones and pilot studies. A successful launch could position Luna as a standard of care for overnight insulin management, offering a less intrusive alternative to pump-based systems.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance Submission for Luna Device50% success
• Q4 2026Positive Results from Pivotal Clinical Trial on Nocturnal Glycemic Control40% success
• Q2 2027Strategic Partnership with Major Insulin Pen Manufacturer or CGM Company30% success